BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora’s Board of Directors or its independent Compensation Committee a ...

Core Insights - The company reported significant growth in the Web 3.0 industry, driven by improvements in the global crypto market and increased market participation [3] - The company successfully transitioned to profitability in the second half of 2025, achieving a net income of RMB 137.7 million (US$ 19.6 million) compared to a net loss of RMB 60.4 million in the same period of 2024 [8][21] Financial Performance - Net revenue for the second half of 2025 increased by 18.1% to RMB 18.7 million (US$ 2.7 million) from RMB 15.9 million in the same period of 2024 [10][11] - Gross loss was RMB 29.1 million (US$ 4.1 million) for the second half of 2025, compared to a gross profit of RMB 11.6 million in the same period of 2024 [10] - Gain on change in fair value of cryptocurrencies was RMB 130.0 million (US$ 18.5 million) for the second half of 2025, compared to a loss of RMB 15.7 million in the same period of 2024 [10][18] - Profit from operations was RMB 60.8 million (US$ 8.7 million) for the second half of 2025, compared to a loss of RMB 55.6 million in the same period of 2024 [10][14] - Basic and diluted earnings per share were approximately RMB 6.2 (US$ 0.9) for the second half of 2025, compared to a loss per share of approximately RMB 6.0 in the same period of 2024 [22] Capital Operations - The company completed two rounds of financing in 2025, which supported its strategic transformation and expansion of crypto asset reserves [5] - A share repurchase program of up to US$ 25.0 million was announced in October 2025, aimed at enhancing shareholder value [7] Product Development - The company launched its new-generation product, the iPollo ClawPC A1 Mini, in March 2026, designed to support the Open Claw AI Agent system [6] - Plans to introduce the Claw OS system and additional hardware products to extend ecological services for AI Agents were also mentioned [6] Strategic Focus - The company aims to monitor emerging industry trends and market dynamics while advancing its crypto asset strategic reserve and pursuing broader opportunities in the AI Agent ecosystem [8]

Core Insights - Sagtec Global Limited is launching its proprietary Sovereign AI Data Center through its subsidiary CL Technologies, marking a strategic pivot towards AI infrastructure and fintech scalability [1][2] - The initiative aims to support millions of daily transactions in retail and financial ecosystems while creating high-margin, recurring revenue opportunities [2][8] Strategic Highlights & Operational Milestones - The Sovereign AI Data Center is set to be completed in Q4 2026 and will utilize NVIDIA's high-performance GPU architecture to enhance transaction processing capabilities [2][7] - The expansion of CL Technologies will enhance the company's ability to manage and analyze high-volume transactional data, supporting future AI applications [4][7] - The initiative will ensure compliance with regulatory requirements through secure, jurisdiction-specific data handling [4] CEO Commentary - The CEO emphasized that owning infrastructure is a natural progression for scaling operations and that the integration of NVIDIA-powered systems will strengthen the company's data foundation for long-term growth [5] Future Revenue Opportunities - The initiative aligns with Sagtec's long-term strategy to develop Infrastructure-as-a-Service (IaaS) and Fintech-as-a-Service offerings, contributing to recurring revenue streams [8]

Core Insights - BioRestorative Therapies, Inc. announced positive results from its Phase 2 clinical trial for hypoxic-cultured mesenchymal stem cells in treating chronic lumbar disc disease, with over 50% of patients reporting significant improvements in pain and function [1][2] - The study showed no adverse events related to dose-limiting toxicities, reinforcing the safety profile of the treatment [1][3] - The company is preparing for a potential Phase 3 clinical trial following alignment with the U.S. FDA on key trial elements [3][4] Clinical Trial Results - 50% or more of treated patients reported improvements greater than 50% in key pain and functional outcome measures [1] - On the Visual Analog Scale (VAS), 53.57% of patients reported over 50% improvement at 26 weeks, increasing to 75% at 52 weeks and remaining at 75% at 104 weeks [6] - For the Oswestry Disability Index (ODI), 53.57% of patients achieved over 50% improvement at 26 weeks, rising to 74.63% at 52 weeks, with 50% maintaining that improvement at 104 weeks [7] - Improvements were also noted in the Roland-Morris Disability Questionnaire (RMDQ) and Functional Rating Index (FRI), with significant percentages of patients showing sustained improvements over time [8][9] Future Development Plans - The company is transitioning from clinical evaluation to registrational planning, preparing for the next stage of clinical development, including protocol planning for Phase 3 [4] - The company aims to continue generating clinical data to support the advancement and potential commercialization of BRTX-100 [4] Company Overview - BioRestorative focuses on developing therapeutic products using adult stem cells, with core programs targeting disc/spine disease and metabolic disorders [10][11] - The lead candidate, BRTX-100, is designed for non-surgical treatment of painful lumbosacral disc disorders, utilizing proprietary technology for stem cell collection and injection [11] - The company also operates a BioCosmeceutical platform, developing products aimed at skin health and longevity [11]

Core Insights - Quantum BioPharma has entered into a strategic partnership with Allucent to support the Phase 2 clinical trial of Lucid-MS, a novel treatment for multiple sclerosis (MS) [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative disorders, with Lucid-MS as its lead compound targeting demyelination in MS [12][13] - The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that could yield up to $250 million [12][13] Clinical Development - The Phase 2 trial of Lucid-MS aims to evaluate its efficacy, safety, and tolerability in MS patients, with an expected initiation in Q2 2026, pending regulatory approvals [3][5] - Allucent will provide comprehensive clinical trial services, including regulatory submissions, site management, patient recruitment, and data management [3][7] Therapeutic Innovation - Lucid-MS is designed to inhibit demyelination, a key factor in MS progression, representing a differentiated approach compared to existing treatments that primarily modulate the immune system [4][5] - The global MS market is projected to exceed $38 billion by 2030, highlighting a significant opportunity for innovative treatments like Lucid-MS [9][11] Market Opportunity - Approximately 2.8 million people worldwide are affected by MS, presenting a substantial healthcare challenge and market potential for new therapies [9][11]

Core Insights - Eikon Therapeutics, Inc. reported significant progress in 2025, including a successful IPO that strengthened its financial position and enabled advancement of multiple clinical programs [2][7]. Pipeline Updates - EIK1001, a dual-agonist for Toll-like receptors 7 and 8, completed enrollment in the TeLuRide-005 Phase 2 study for non-small cell lung cancer, with data expected in the second half of 2026 [3][4]. - EIK1003 and EIK1004, next-generation PARP1 inhibitors, are under evaluation in various trials, with EIK1003 expected to initiate a new cohort in the second half of 2026 [5]. - EIK1005, a WRN helicase inhibitor, has shown in vitro activity in MSI-high cancer cells and is currently in a Phase 1/2 trial [4][5]. Financial Results - As of December 31, 2025, Eikon had cash, cash equivalents, and marketable securities totaling $336.0 million, bolstered by an IPO that raised $381.2 million in February 2026 [7][17]. - Research and Development (R&D) expenses for Q4 2025 were $65.2 million, a 21% increase from Q4 2024, driven by clinical trial activities and increased operational costs [8]. - General and Administrative (G&A) expenses for Q4 2025 were $17.9 million, a 29% increase from the previous year, primarily due to higher compensation costs and depreciation expenses [9]. - The net loss attributable to common stockholders for Q4 2025 was $79.7 million, compared to $64.9 million in the prior year, with a total net loss of $333.6 million for the full year 2025 [10][16].

Core Insights - Virtuix Inc. has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Postgraduate School (NPS) to evaluate its Omni One system for military training and simulation applications [1][2][5] - This agreement marks Virtuix's first formal research collaboration with the U.S. Navy and signifies the company's growing presence in the defense market, building on previous sales to various branches of the U.S. military [3][4] Group 1: Agreement Details - The CRADA will allow NPS researchers to assess the effectiveness of omni-directional navigation technology for military training [1][2] - The agreement supports the adoption of Virtuix's Virtual Terrain Walk (VTW) technology for military and first responder applications [2] Group 2: Technology and Applications - The Virtual Terrain Walk system enables soldiers to familiarize themselves with environments before deployment, utilizing AI-driven 3D reconstruction to create photorealistic virtual worlds [4] - Users can engage in physical activities such as walking, running, and crouching within these virtual environments for mission planning and training purposes [4] Group 3: Market Expansion - Virtuix's collaboration with NPS complements its existing partnerships with the U.S. Army, U.S. Air Force, and U.S. Marine Corps, indicating a broader acceptance of its technology in defense [3][4] - The company aims to leverage insights from this collaboration to further develop its Virtual Terrain Walk technology and enhance its defense market presence [4]

Core Insights - MediPharm Labs Corp. reported an 8% annual revenue growth in 2025, driven by its international medical cannabis strategy, with international revenue contributing over 50% of total revenue [2][4][8] - The company ended 2025 with a strong balance sheet, virtually debt-free, and over $10 million in cash, positioning it favorably compared to industry peers [3][12][13] Financial Performance - Total revenue for FY 2025 was $45.1 million, an increase of 8% from 2024, with international medical cannabis revenue reaching $25.2 million, a 43% increase year-over-year [4][5][8] - Q4 2025 revenue was $11.1 million, slightly down from $12.0 million in Q4 2024, attributed to timing and mix differences [4][10] - Gross profit for FY 2025 was $14 million, representing a 31% margin, an increase from $12.8 million in 2024 [7][8] Operational Highlights - The company launched new products in Europe and Australia, including novel metered dose inhalers, and executed its first commercial shipments to France and Brazil [5][6][8] - Canadian medical cannabis revenue for Q4 2025 was $3.2 million, reflecting an 8% sequential increase from Q3 2025 [6][10] Cost Management - Operating expenses for 2025 were $20.9 million, a decrease of $0.7 million from the previous year, with adjusted operating expenses at $16.8 million, down 14% year-over-year [9][12] - Adjusted EBITDA for 2025 was negative $1.6 million, an improvement of $0.3 million over 2024 [9][21]

Core Viewpoint - Fancamp Exploration Ltd. has acquired up to 3.0% net smelter returns royalties on certain iron ore properties in the Labrador Trough for a total cash consideration of $1,765,000, which is expected to enhance the company's cash flow and support its strategic reorganization through a spin-out of its core exploration projects into a new subsidiary, Goldera Exploration Ltd. [1][2][3] Acquisition Details - The Royalty Acquisition includes royalties on a notable open pit mineable iron ore deposit located approximately 25 kilometers northwest of Schefferville, Quebec [1] - The acquisition is part of Fancamp's strategy to seek high-growth opportunities while reorganizing its assets [2] Spin-Out Transaction - Fancamp plans to complete the spin-out of Goldera Exploration Ltd. in Q2 of 2026, pending necessary approvals [3] - The spin-out aims to unlock shareholder value by creating two focused, publicly traded companies, allowing shareholders to participate in both growth streams [3] Exploration Projects - Goldera will advance exploration at the McIntyre Brook and Riley Brook mineral properties, which are part of a joint venture with Acadian Gold Corp. [4][7] - McIntyre Brook has shown promising gold mineralization, with a drilling program yielding results of 4 meters at 1.45 g/t Au [6] - Riley Brook has identified significant soil anomalies for gold and other minerals, indicating potential for further exploration [7] Egan Property - Fancamp has an option agreement to earn up to an 80% interest in the Egan Gold mineral property, located strategically between Timmins and Kirkland Lake [10] - The Egan Property has demonstrated high-grade surface results, with grab samples showing up to 105 g/t gold [10] - Goldera plans to conduct a comprehensive exploration program at the Egan Property, including airborne geophysics and drilling anticipated by late Q3 2026 [10] Share Buyback Program - Fancamp has acquired approximately 2.4 million common shares for cancellation under its normal course issuer bid, representing about 1% of its issued and outstanding shares [12] - This buyback reflects the company's belief that its shares are undervalued based on its asset portfolio and future prospects [12]

Core Viewpoint - WISeKey's subsidiary WISeSat.Space has successfully launched its 21st satellite, WISeSat 4.0, into Low Earth Orbit (LEO) as part of SpaceX's Transporter-16 mission, marking a significant step towards establishing a quantum-secure space internet [1][2][5]. Group 1: Satellite Launch and Technology - The WISeSat 4.0 satellite was launched from Vandenberg Space Force Base in California, deploying over 100 satellites during a 57-minute launch window [2]. - This launch signifies the operational deployment of a new generation of WISeSat satellites aimed at providing quantum-secure, high-speed, low-latency broadband connectivity [2][3]. - WISeSat 4.0 integrates WISeKey's trusted Root of Trust with SEALSQ's Post-Quantum chip, facilitating secure machine-to-machine transactions and decentralized service execution in orbit [3][5]. Group 2: Future Plans and Developments - The average lifespan of WISeSat satellites is approximately five years, necessitating continuous renewal to incorporate next-generation technologies and enhance performance [4]. - Additional WISeSat deployments are planned for 2026 and 2027, focusing on expanding coverage, increasing bandwidth, and integrating AI-driven analytics for security monitoring [4]. - WISeSat is developing the world's first commercial Quantum Spatial Orbital Cloud (QSOC), which will deploy a 100-satellite constellation for quantum key distribution and other services by 2033 [6][7]. Group 3: SEALCOIN and Economic Implications - SEALCOIN serves as the transactional layer for WISeKey's space-based digital infrastructure, enabling secure, autonomous machine-to-machine economic interactions [10][13]. - The protocol allows connected devices and satellites to exchange value and authenticate each other without human intervention, supporting applications like autonomous logistics and real-time service provisioning [10][11]. - SEALCOIN aims to extend the digital economy into space, allowing satellites and connected devices to operate as autonomous economic agents [11].